首页 News 正文

Novo Nordisk Ultra Long acting Insulin Global First Batch Expected Within Two Months

六月清晨搅
230 0 0

[The first batch of Novo Nordisk ultra long-acting insulin in the world is expected to be within two months] A few days ago, the Commission on Human Medicines (CHMP) of the European Drug Administration adopted a positive opinion, suggesting that Awiqli (a weekly preparation of basic insulin, Icodec insulin) be given a marketing license for the treatment of adult diabetes. Novo Nordisk (NVO.US) is expected to receive the final market approval from the European Commission within approximately two months. In addition to the European Union, Novo Nordisk also completed the listing application submission to the US FDA and Chinese regulatory authorities in the second quarter of 2023, and is currently waiting for the review results to be announced.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

六月清晨搅 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    30